BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 15,000 Shares

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 15,000 shares of the firm’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $96.09, for a total value of $1,441,350.00. Following the sale, the chief executive officer directly owned 553,209 shares of the company’s stock, valued at approximately $53,157,852.81. This trade represents a 2.64% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $96.49, for a total value of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The stock was sold at an average price of $99.45, for a total value of $4,077,450.00.
• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $96.93, for a total transaction of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The stock was sold at an average price of $96.31, for a total transaction of $1,974,355.00.
• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The shares were sold at an average price of $97.78, for a total transaction of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The stock was sold at an average price of $99.20, for a total transaction of $3,670,400.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The stock was sold at an average price of $103.52, for a total transaction of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $102.85, for a total transaction of $4,628,250.00.

BioNTech Stock Down 0.9%

BioNTech stock opened at $95.83 on Thursday. The company has a market capitalization of $24.23 billion, a PE ratio of -12.24 and a beta of 1.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. BioNTech SE Sponsored ADR has a fifty-two week low of $79.52 and a fifty-two week high of $124.00. The firm has a 50 day moving average price of $97.17 and a 200 day moving average price of $95.00.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The firm had revenue of $122.31 million for the quarter, compared to analyst estimates of $180.18 million. During the same quarter last year, the company earned ($1.60) earnings per share. The firm’s revenue for the quarter was down 59.5% on a year-over-year basis. Research analysts expect that BioNTech SE Sponsored ADR will post -6.33 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on BNTX. BMO Capital Markets cut BioNTech from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $128.00 to $105.00 in a report on Tuesday, September 8th. Citigroup reduced their price target on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating on the stock in a research report on Wednesday, August 5th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of BioNTech in a research note on Friday, June 5th. Jefferies Financial Group reiterated a “buy” rating on shares of BioNTech in a report on Monday, June 1st. Finally, Morgan Stanley decreased their price target on shares of BioNTech from $126.00 to $119.00 and set an “overweight” rating for the company in a research report on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $126.00.

Hedge Funds Weigh In On BioNTech

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Larson Financial Group LLC lifted its stake in shares of BioNTech by 86.4% in the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after purchasing an additional 127 shares in the last quarter. AlphaCentric Advisors LLC increased its position in BioNTech by 5.7% during the 1st quarter. AlphaCentric Advisors LLC now owns 5,616 shares of the company’s stock worth $499,000 after purchasing an additional 305 shares in the last quarter. USS Investment Management Ltd raised its holdings in BioNTech by 1.2% in the first quarter. USS Investment Management Ltd now owns 32,577 shares of the company’s stock valued at $2,854,000 after buying an additional 382 shares during the period. Integrated Wealth Concepts LLC purchased a new position in BioNTech in the second quarter valued at approximately $39,000. Finally, Marks Group Wealth Management Inc lifted its position in BioNTech by 16.0% during the first quarter. Marks Group Wealth Management Inc now owns 3,454 shares of the company’s stock valued at $307,000 after buying an additional 476 shares in the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.